Versican belongs to the family of the large aggregating chondroitin sulfate proteoglycans located primarily within the extracellular matrix (ECM). Versican, like other members of its family, has unique N-and C-terminal globular regions, each with multiple motifs. A large glycosaminoglycan-binding region lies between them. This review will begin by outlining these structures, in the context of ECM proteoglycans. The diverse binding partners afforded to versican by virtue of its modular design will then be examined. These include ECM components, such as hyaluronan, type I collagen, tenascin-R, fibulin-1, and -2, fibrillin-1, fibronectin, P-and L-selectins, and chemokines. Versican also binds to the cell surface proteins CD44, integrin β1, epidermal growth factor receptor, and P-selectin glycoprotein ligand-1. These multiple interactors play important roles in cell behaviour, and the roles of versican in modulating such processes are discussed.
Glomerulonephritis is believed to result commonly from Ab-mediated glomerular injury. However, Ab-associated mechanisms alone cannot explain many cases of human glomerulonephritis. We developed a rat model of human anti-glomerular basement membrane (GBM) disease to investigate T cell and Ab response, and their associations with the disease. A single immunization of highly denatured recombinant mouse collagen IVα3 chain noncollagen domain 1 (rCol4α3NC1) induced severe glomerulonephritis in 100% of Wistar Kyoto rats, 33% of which died of this disease around day 35 postimmunization. The renal pathology demonstrated widespread glomerular damage and a mononuclear cell infiltration within the interstitial tissue. T cells from immunized rats responded not only to rCol4α3NC1, but also to isolated rat GBM. Sera Abs to rCol4α3NC1 were detectable in 100% of the rats, but only 20% of the rats had low levels of Ab to isolated rat GBM by Western blot, and none by immunofluorescence. Furthermore, IgG/M binding to or C3 deposition on endogenous GBM in immunized rats were not detected in most of the experimental rats, and showed no statistical correlation with disease severity. Additionally, no electronic dense deposition in the glomeruli was detected in all rats. Those data revealed a disassociation between the disease and anti-GBM Ab. T cell-mediated mechanisms, which are currently under our investigation, may be responsible for the glomerular disease.
Late-onset Alzheimer’s disease (AD) remains a medical mystery. Recent studies
have linked it to impaired repair of aged neurons. Potential involvement of
interleukin33 (IL33) in AD has been reported. Here we show that IL33, which was
expressed by up to 75% astrocytes in the aged brains, was critical for repair
of aged neurons. Mice lacking Il33 gene
(Il33−/−) developed AD-like
disease after 60–80 weeks, which was characterized by tau abnormality and a
heavy loss of neurons/neurites in the cerebral cortex and hippocampus accompanied
with cognition/memory impairment. We detected an abrupt aging surge in the
cortical and hippocampal neurons at middle age (40 weeks). To counter the aging
surge, wild-type mice rapidly upregulated repair of DNA double-strand breaks (DSBs)
and autophagic clearance of cellular wastes in these neurons.
Il33−/− mice failed to do so, but
instead went on to develop rapid accumulation of abnormal tau, massive DSBs and
abnormal autophagic vacuoles in these neurons. Thus, uncontrolled neuronal aging
surge at middle age due to lack of IL33 resulted in neurodegeneration and late-onset
AD-like symptome in Il33−/− mice. Our
study also suggests that the aging surge is a time to search for biomarkers for early
diagnosis of AD before massive neuron loss.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.